How Metaverse is Set to Transform the Healthcare Dynamics?


Nkarta’s Anti-CD19 Allogeneic CAR-NK Cell Thera...

FDA Grants Orphan Drug Designation to AUM302 for Neuroblastoma A global clinical-stage biotech company, AUM Biosciences, focused on discovering and developing precision oncology therapeutics, decla...

Dec 06, 2022

MedTech News for Empatica, ClariPi, Sony, Mainstay Medical, Zimmer
Mainstay Medical’s ReActiv8-C Study; Swing Therapeutics Announced Results from Studies of Stanza; FDA Approves Empatica’s Health Monitoring Platform; FDA Clearance to Persona OsseoTi Keel Tibia System; ClariPi Joins Siemens Healthineers Digital Marketplace; Sony Launches Cloud-based Solution for Flow Cytometry Data Analysis

Mainstay Medical Published Post-Market Clinical Trial Data from Ongoing ReActiv8®-C Study  On November 22, 2022, Mainstay Medical, a medical devices company, announced that the data from the ReActiv8®-C study, a single-centre, real-world study with a one-year clinical follow-up of selected patients, is publ...

Find More
Major Technology and Devices in Sleeping Disorders Market
How is Technology Addressing the Sleeping Disorders?

Sleep disorders (or sleep-wake disorders) are one of the major health burdens in today's time. Sleep is a fundamental process in human life and well-being, and these disorders largely remain untreated or, more often, misdiagnosed as psychiatric problems. Sleep disorders affect and change the way that a person sleep...

Find More
RNA Interference: New Class of Drugs In The Fight Against Disease

RNA interference (RNAi) is a fundamental gene-silencing pathway in eukaryotic cells that involves an enzyme called dicer cleaving long pieces of double-stranded RNA into shorter fragments called siRNAs that can cleave complementary mRNA sequences with the help of the RISC complex and argonaute. RNA interference ...

Find More

More Views & Analysis

MedTech News for Medtronic, Penumbra, and Genesis
Medtronic Launches Infusion Set for Insulin Pumps; Penumbra’s Virtual Reality-Based Rehabilitation System; FDA Approval to Genesis’s Chocolate Touch® Drug-coated Balloon PTA Catheter; FDA Nod to AEYE’s AI-based Autonomous Screening; Alpheus Medical Treats First High-Grade Glioma Brain Cancer Patient with its Proprietary Platform; Karidum’s Next Generation Globe® Pulsed Field System

Medtronic Launches World's First and Only Infusion Set for Insulin Pumps that Doubles Wear Time up to 7 days in the US  On November 15, 2022, Medtronic plc, a global leader in healthcare technology, announced the US launch of the Medtronic Extended infusion set, the first and only infusion set labeled for up to ...

Find More

Pharma News for Genentech, Sanofi, Merck
Genentech’s gantenerumab Fails in Phase III Trial; CHMP Recommends’ Dupixent; FDA Clears Imfinzi and Imjudo with chemotherapy; NICE Recommends Ipsen’s Cabometyx (cabozantinib); NICE Backs KEYTRUDA; NRG Announces £16 Million Series A Funding; FDA Backs AstraZeneca’s PT027

Genentech’s gantenerumab Fails in Phase III Trial for Alzheimer’s Disease In yet another setback for an amyloid-targeting drug, Roche's Genentech division has reported disappointing top-line results from its highly anticipated phase III trial of gantenerumab in early Alzheimer's disease. The failure is entirely ...

Find More

How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape?

Mitsubishi replacing RADICAVA’s Intravenous (IV) formulation with Oral. Opinion on Amylyx Pharma’s recent approval, RELYVRIO  The amyotrophic lateral sclerosis treatment landscape is stringent and includes multidisciplinary care, such as physical therapy, speech therapy, dietary counseling, heat or whirlpoo...

Find More

Technology Trends and Innovations in Dementia Care
How are Technological Trends and Innovations Reshaping the Dementia Care?

Dementia is a leading neurological condition that affects the brain and worsens over time. It leads to progressive cognitive and functional degeneration and results in several neuropsychiatric symptoms. As per the estimate, about 55 million people globally live with dementia, and around 10 million new cases are obs...

Find More

MedTech News for Enspectra, Mentice, and EndoStim
FDA Approval to DePuy TELIGEN System; FDA Breakthrough Device Designation for the EndoStim System; GE and Accuray Announces Collaboration; Mentice and Acandis Announces a Three-Year Agreement; Indigo Diabetes Enrolled First Participant in the Shine Clinical Trial; FDA IDE Approval to MedAlliance’s SELUTION SLR

DePuy Synthes Received FDA Approval for TELIGEN™ System  On October 20, 2022, DePuy Synthes, The Orthopaedics Company of Johnson & Johnson, provides one of the most comprehensive orthopedics portfolios in the world that helps heal and restore movement for the millions of patients, announced that ...

Find More

Spinal Cord Injury Rehabilitation Technology and Trends
Navigating the Emerging Trends and Technologies in the Spinal Cord Injury Rehabilitation Segment

The incidence and prevalence of traumatic spinal cord injury (SCI) worldwide have increased over time. As per the study by Weizhong Ding et al., globally, there were 0.9 million incident cases, 20.6 million prevalent cases, and 6.2 million YLDs of total SCI in 2019. Similarly, as per the data presented by WHO, ever...

Find More

Rheumatoid Arthritis
Rheumatoid Arthritis...

Rheumatoid Arthritis (RA) is a chronic, inflammatory autoimmune disease that leads to progressive an.....

Find More
Toll-like receptors (TLR) 7 and 8 Agonist
Toll-like receptors (TLR)...

Toll-like receptors (TLR) 7 and 8 are functionally localized to endosomes and recognize specific RNA.....

Find More
Gene Therapies
Gene Therapies

Gene therapies are regarded as one of the potential revolution in the Pharmaceutical field and Healt.....

Find More